Acadia Pharmaceuticals ACAD Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $268.06M+9.7% | $283.99M+9.4% | $278.63M+11.3% | $264.57M+9.3% | $244.32M+18.7% | ||
| $24.79M+21.6% | $26.23M+20.3% | $21.65M+14.8% | $20.73M+13.7% | $20.39M-11.1% | ||
| $243.27M+8.6% | $257.76M+8.4% | $256.99M+11.0% | $243.83M+9.0% | $223.93M+22.4% | ||
| 90.8%-0.9pp | 90.8%-0.8pp | 92.2%-0.2pp | 92.2%-0.3pp | 91.7%+2.8pp | ||
| $76.87M-1.8% | $84.76M-15.9% | $87.83M+31.9% | $77.95M+2.3% | $78.27M+31.1% | ||
| $171.02M+35.3% | $155.62M+19.6% | $133.4M+0.1% | $133.51M+14.0% | $126.37M+17.0% | ||
| $272.68M+21.2% | $266.6M+151% | $242.88M+11.0% | $232.19M+9.8% | $225.03M+18.0% | ||
| -$4.62M-124% | $17.39M-88.7% | $35.76M+13.0% | $32.37M+6.4% | $19.29M+26.8% | ||
| -1.7%-9.6pp | 6.1%-53.0pp | 12.8%+0.2pp | 12.2%-0.3pp | 7.9%+0.5pp | ||
| $8.06M+1.9% | $8.33M+18.9% | $8.25M+25.2% | $7.24M+13.9% | $7.9M+43.5% | ||
| $542K-7.8% | $596K+3.7% | $593K+3.0% | $594K+53.9% | $588K+106% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $3.98M-85.7% | $26.32M-83.7% | $44.6M+14.9% | $40.21M+8.1% | $27.78M+32.3% | ||
| $344K-96.1% | -$247.25M-1,526% | -$27.18M-550% | $13.55M+257% | $8.79M+97.7% | ||
| $3.64M-80.8% | $273.57M+90.3% | $71.78M+119% | $26.67M-20.1% | $18.99M+14.7% | ||
| 1.4%-6.4pp | 96.3%+41.0pp | 25.8%+12.7pp | 10.1%-3.7pp | 7.8%-0.3pp | ||
| $0.02-81.8% | $1.61+87.2% | $0.42+110% | $0.16-20.0% | $0.11+10.0% | ||
| $0.02-81.8% | $1.62+86.2% | $0.43+115% | $0.16-20.0% | $0.11+10.0% | ||
| 172.7M+3.0% | 169.9M+2.1% | 170.7M+2.7% | 168.7M+1.5% | 167.7M+0.6% | ||
| 170.5M+2.2% | 168.4M+1.6% | 168.8M+1.7% | 167.8M+1.4% | 166.8M+1.2% | ||
| $8.06M+1.9% | $8.33M+18.9% | $8.25M+25.2% | $7.24M+13.9% | $7.9M+43.5% | ||
| $271K+18.3% | $202K-10.6% | $227K+0.4% | $213K-5.8% | $229K-5.4% | ||
| —— | $6.29M+28.9% | $6.29M+28.9% | $6.29M+28.9% | $6.29M+28.9% | ||
| $1.34M-29.4% | -$10.84M-275% | $1.65M+306% | $2M+264% | $1.9M+6.4% | ||
| $23.56M+20,408% | -$68.39M-322% | $27.78M+110% | $21.47M+44.6% | -$116K-101% | ||
| $32K-94.5% | $850K— | $700K+698% | $721K— | $585K— | ||
| -$6.5M-441% | $5.25M+92.0% | -$14.66M-595% | $8.59M+688% | $1.91M+149% | ||
| $542K-7.8% | $596K+3.7% | $593K+3.0% | $594K+53.9% | $588K+106% | ||
| $5.21M— | $4.01M+784% | $388K+454% | $297K— | $0— | ||
| $4.23M+130% | $22.67M+1,051% | $9.42M+3,416% | $15.96M+348% | $1.84M+76.2% | ||
| $86.5M-33.9% | $105.75M-5.5% | $125.59M+81.7% | $131.39M+61.2% | $130.8M+97.8% | ||
| $268.06M+9.7% | $283.99M+9.4% | $278.63M+11.3% | $264.57M+9.3% | $244.32M+18.7% | ||
| $14.7M+29.2% | $13.24M+26.7% | $13.18M-49.6% | $14.34M-8.6% | $11.38M-22.8% | ||
| -$4.62M-124% | $17.39M-88.7% | $35.76M+13.0% | $32.37M+6.4% | $19.29M+26.8% | ||
| -$1.62M-107% | $20.32M-87.2% | $38.71M+13.1% | $35.31M+7.0% | $22.24M+7.2% | ||
| -$1.62M-107% | $20.32M-87.2% | $38.71M+13.1% | $35.31M+7.0% | $22.24M+7.2% | ||
| -0.6%-9.7pp | 7.2%-54.0pp | 13.9%+0.2pp | 13.3%-0.3pp | 9.1%-1.0pp | ||
| -$4.62M-124% | $17.39M-88.7% | $35.76M+13.0% | $32.37M+6.4% | $19.29M+26.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Acadia Pharmaceuticals's revenue?
- Acadia Pharmaceuticals (ACAD) generated $1.1B in revenue over the trailing twelve months, up 9.9% year over year.
- Is Acadia Pharmaceuticals profitable?
- Acadia Pharmaceuticals reported $375.7M in net income over the trailing twelve months, a 34.3% net margin.
- What are Acadia Pharmaceuticals's profit margins?
- Gross margin is 91.5% and operating margin is 7.4%, with a 34.3% net margin.
- What is Acadia Pharmaceuticals's earnings per share?
- Acadia Pharmaceuticals's diluted EPS over the trailing twelve months is $2.21.
- Where does Acadia Pharmaceuticals's income statement data come from?
- Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
